Search results
Showing 436 to 450 of 1835 results for carers
This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.
help secondary schools and providers to effectively engage with parents and carers as part of a whole-school approach to promote and...
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available...
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.
In development Reference number: GID-HTE10011 Expected publication date: TBC
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?...
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]
In development Reference number: GID-TA11058 Expected publication date: TBC
In development Reference number: GID-TA11674 Expected publication date: 07 May 2026
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used